ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.

@article{Russo2013ABT737RI,
  title={ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.},
  author={Maria Russo and Carmela Spagnuolo and Silvestro Volpe and Idolo Tedesco and Stefania Bilotto and Gian Luigi Russo},
  journal={Biochemical pharmacology},
  year={2013},
  volume={85 7},
  pages={
          927-36
        }
}
Chronic lymphocytic leukemia (CLL) is the most frequent form of leukemia in adult population and despite numerous studies, it is considered an incurable disease. Since CLL is characterized by overexpression of pro-survival Bcl-2 family members, treatments with their antagonists, such as ABT-737, represent a promising new therapeutic strategy. ABT-737 is a BH3 mimetic agent which binds Bcl-2, Bcl-XL and Bcl-w with high affinity, while weakly interacts with Mcl-1 and Bfl-1. Previous studies… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia

  • Oncotarget
  • 2017
VIEW 9 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Sorafenib potentiates ABT-737-induced apoptosis in human oral cancer cells.

  • Archives of oral biology
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 56 REFERENCES